I last reviewed McDonald's (MCD) in this March 19, 2022 post. In that post, I disclose my March 7 purchase of an additional 100 shares at ~$226 in a 'Side' account in the FFJ Portfolio while on a ski trip. At the time, the most recently available financial results were those for FY2021. Now that [...]
Unfortunately, the number of bargains presented to investors from mid-September through mid-October has diminished of late. However, CME Group (CME) is low-risk and attractively valued. This makes it an attractive investment at a time when investors should reduce risk. In addition to this piece of good news, CME is scheduled to declare its 'special annual [...]
I last reviewed Abbvie Inc. (ABBV) in this February 3, 2022 post, at which time I concluded shares to be overvalued. At the time of that post, ABBV had just released Q4 and FY2022 results. Given that ABBV issued Q3 and YTD2022 results on October 28, 2022, I take this opportunity to revisit this holding. [...]
Based on the Q3 and FY2022 results released on October 27, 2022, S&P Global (SPGI) is attractively valued with strong recurring revenue and expense discipline. In contrast, following the release of Q2 and YTD 2022 results, I concluded in my August 2, 2022 post, that it would be wise to wait for a better valuation. [...]
In my July 29, 2022 Automatic Data Processing (ADP) post, I conclude that a share price pullback to the mid $220 range was not unreasonable once the euphoria waned following the release of ADP's strong FY2022 results and FY2023 outlook. ADP's share price rose after that post. In mid-August, however, the share price commenced a [...]
I last reviewed Fortive (FTV) in this May 2, 2022 post at which time it had recently released Q1 2022 results and its FY2022 outlook. With the release of Q3 and YTD2022 results and updated FY2022 outlook, I now revisit FTV. Business Overview A good explanation of FTV, including high-level information about acquisitions and divestitures, [...]
I last reviewed Merck & Co., Inc. (MRK) in this January 13, 2022 guest post at Dividend Power. At the time of that post, MRK's Q3 2021 results were the most recent. With the release of Q3 and YTD2022 results and a revised FY2022 outlook on October 27, 2022, I take this opportunity to revisit [...]
Benefit from Blackstone's (BX) durable model. This durable model along with the benefits of thematic investing enables BX to invest on behalf of pension funds and other leading institutions so as to continue expanding even in the most difficult of times. With $950.9B in total Assets Under Management (AUM) at the end of Q3 2022, [...]
I initiated a 200 Union Pacific (UNP) share position @ ~$142/share on March 11, 2020 through one of the 'Side' accounts within the FFJ Portfolio. In hindsight, I should have acquired more shares because that was the last time, up until just recently, that I considered UNP to be undervalued. My prior UNP review [...]
In early January 2022 I initiated a Danaher (DHR) position and shared the following in my January 6 post: Based on DHR's track record and the extent to which the Life Sciences and Diagnostics segments have grown, I would not be surprised to learn of another spin-off in the future. Fast forward to September [...]